Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib as first-line therapy for recurrent/metastatic intrahepatic cholangiocarcinoma (Phase II, single-arm)
ChiCTR2000034166Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in intrahepatic cholangiocarcinoma (ICC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Started Jun 2020; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2000034166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034166.